Your Health, We Care
Erlotinib® is indicated for:
The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as confirmed by an FDA-approved test. It may be used as first-line therapy, maintenance therapy, or second-line or later-line therapy following disease progression after at least one prior chemotherapy regimen.
Usage Restrictions:
The safety and effectiveness of Erlotinib in NSCLC patients with other EGFR mutations have not been established.
Concomitant use of Erlotinib with platinum-containing chemotherapy is not recommended.
Erlotinib in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer.
FDA，2016.10
